Guangdong Expects To Reduce Essential Drug Prices By 40%
This article was originally published in PharmAsia News
Executive SummaryGuangdong expects to lower drug prices by over 40% by selecting only one drug supplier for each essential drug
You may also be interested in...
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
Perrigo has received US FDA approval for a generic version of Teva’s ProAir albuterol inhaler. The firm is immediately launching a “limited quantity” but is also ramping up production with partner Catalent to meet future demand.
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.